BTIG raised the firm’s price target on GeneDx (WGS) to $200 from $165 and keeps a Buy rating on the shares as part of a broader research note reviewing 2025 for Diagnostics and Tools. The firm also named the stock its 2026 Top Pick. Along with Guardant Health (GH), the company is still in early innings of penetrating very large markets, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS:
- TSLA, META: Cathie Wood Dumps These Two Magnificent 7 Stocks, Doubles Down on Trade Desk (TTD) Instead
- WGS, WRD, IRDM: Cathie Wood Ramps Up Buying in GeneDx and WeRide, Trims Exposure in Iridium stock
- GeneDx price target raised to $160 from $140 at Piper Sandler
- GeneDx management to meet with Piper Sandler
- GeneDx price target raised to $165 from $140 at BTIG